All Data
Brightest Minds in the CDMO industry - From early Development to Commercial Manufacturing
Lead Product(s): Opicapone
Therapeutic Area: Neurology Product Name: Ongentys
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: Bial
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement October 01, 2020
Details:
The new agreement provides both companies with a long-term partnership that will ensure continued supply for patients across the globe. Opicapone (Ongentys) is approved in Europe, USA, South Korea, Taiwan, Australia and Japan.
Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE
Lead Product(s): Levodopa,Carbidopa,Entacapone
Therapeutic Area: Neurology Product Name: Undisclosed
Highest Development Status: Approved Product Type: Small molecule
Partner/Sponsor/Collaborator: STADA Arzneimittel
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Acquisition October 02, 2020
Details:
By acquiring Lobsor Pharmaceuticals, STADA gains rights to a triple fixed combination (levodopa, carbidopa, entacapone), delivered via modern pump technology, that has already been successfully launched in Nordic countries.
Active Pharmaceutical Ingredients
Finished Drug Formulations
Prices
Excipients
Services
Marketplace
